Regencell Bioscience Holdings Ltd Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q2 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Regencell Bioscience Holdings Ltd quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q2 2019 to Q2 2024.
  • Regencell Bioscience Holdings Ltd Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending June 30, 2024 was $2.79M, a 20.9% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $2.79M +$482K +20.9% Jun 30, 2024 20-F 2024-10-25
Q2 2023 $2.31M +$848K +58.2% Jun 30, 2023 20-F 2024-10-25
Q2 2022 $1.46M +$798K +121% Jun 30, 2022 20-F 2024-10-25
Q2 2021 $660K +$222K +50.8% Jun 30, 2021 20-F 2023-10-27
Q2 2020 $437K +$134K +44.2% Jun 30, 2020 20-F 2022-10-31
Q2 2019 $303K Jun 30, 2019 20-F 2021-10-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.